一项在原发性胆汁性胆管炎患者中评估seladelpar的II期、随机、开放标签、52周研究
这项52周II期剂量探索开放标签研究将原发性胆汁性胆管炎且疾病进展风险患者随机分为seladelpar 5 mg/日组(n=53)或10 mg/日组(n=55),另在 interim 分析后于英国站点分配2 mg/日组(n=11)治疗12周,随后可上调至10 mg/日。主要终点为第8周碱性磷酸酶(ALP)较基线变化,结果显示2 mg、5 mg、10 mg组ALP分别降低26±2.8%、33±2.6%、41±1.8%(均p≤0.005),第52周应答维持或改善,且未出现治疗相关严重不良事件。
要点
- 第8周ALP较基线平均降低:2 mg组26±2.8%、5 mg组33±2.6%、10 mg组41±1.8%,均p≤0.005。
- 第52周复合应答率:2 mg组64%、5 mg组53%、10 mg组67%;ALP正常化率分别为9%、13%、33%。
- 无治疗相关严重不良事件,4例因不良事件停药,未观察到瘙痒加重。
核心结论
- Seladelpar在疾病进展风险的原发性胆汁性胆管炎患者中显示出稳健、剂量依赖性、有临床意义且持久的胆汁淤积和炎症生化标志物改善。
- Seladelpar似乎安全且耐受良好,未伴有瘙痒增加。
研究设计与样本
- 52周、II期、剂量探索、开放标签研究,患者随机(1:1)接受seladelpar 5 mg/日(n=53)或10 mg/日(n=55),或分配至2 mg/日(n=11; interim分析后英国站点)治疗12周。
- 随后剂量可上调至10 mg/日。
- 主要疗效终点为第8周ALP较基线变化。
主要发现
- 基线平均ALP在2 mg、5 mg、10 mg队列分别为300、345、295 U/L。
- 第8周ALP较基线平均降低:2 mg组(n=11)26±2.8%、5 mg组(n=49)33±2.6%、10 mg组(n=52)41±1.8%(均p≤0.005)。
- 第52周,2 mg和5 mg队列分别有91%和80%的患者在剂量上调后应答维持或改善。
- 第52周复合应答率(ALP<1.67×ULN、ALP降低≥15%且总胆红素正常)在2 mg、5 mg、10 mg队列分别为64%、53%、67%;ALP正常化率分别为9%、13%、33%。
- 5 mg和10 mg队列瘙痒视觉模拟评分降低。
关键数值与推荐
- 21%的患者有肝硬化,71%有瘙痒。
- 无治疗相关严重不良事件,4例因不良事件停药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary cholangitis (PBC) at risk of disease progression (alkaline phosphatase [ALP] ≥1.67xupper limit of normal [ULN]) who were receiving or intolerant to ursodeoxycholic acid. METHODS: In this 52-week, phase II, dose-ranging, open-label study, patients were randomized (1:1) to seladelpar 5 mg/day (n = 53) or 10 mg/day (n = 55) or assigned to 2 mg/day (n = 11; United Kingdom sites after interim analysis) for 12 weeks. Doses could then be uptitrated to 10 mg/day. The primary efficacy endpoint was ALP change from baseline to Week 8. RESULTS: Mean baseline ALP was 300, 345, and 295 U/L in the 2 mg, 5 mg, and 10 mg cohorts, respectively. Twenty-one percent of patients had cirrhosis, 71% had pruritus. At Week 8, mean ± standard error ALP reductions from baseline were 26 ± 2.8%, 33 ± 2.6%, and 41 ± 1.8% in the 2 mg (n = 11), 5 mg (n = 49), and 10 mg (n = 52) cohorts (all p ≤0.005), respectively. Responses were maintained or improved at Week 52, after dose escalation in 91% and 80% of the 2 mg and 5 mg cohorts, respectively. At Week 52, composite response (ALP <1.67xULN, ≥15% ALP decrease, and normal total bilirubin) rates were 64%, 53%, and 67%, and ALP normalization rates were 9%, 13%, and 33% in the 2 mg, 5 mg, and 10 mg cohorts, respectively. Pruritus visual analog scale score was decreased in the 5 mg and 10 mg cohorts. There were no treatment-related serious adverse events, and 4 patients discontinued due to adverse events. CONCLUSIONS: Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus. GOV NUMBER: NCT02955602 CLINICALTRIALSREGISTER. EU NUMBER: 2016-002996-91 LAY SUMMARY: Current treatment options for patients living with primary biliary cholangitis (PBC) are not optimal due to inadequate effectiveness or undesirable side effects. Patients with PBC who took seladelpar, a new treatment being developed for PBC, at increasing doses (2, 5, or 10 mg/day) for 1 year had clinically significant, dose-dependent improvements in key liver tests. Treatment appeared safe and was not associated with any worsening in patient self-reported itch scores.
引用
- Bowlus CL, Galambos MR, Aspinall RJ, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022. PMID: 35367282. doi:10.1016/j.jhep.2022.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。